Clinical Trial Update: Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy [Phase 2]

View source ↗

Summary

Phase II study evaluating Anlotinib in patients with advanced renal cell carcinoma after TKI therapy failure or intolerance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN